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Dermal drug delivery system that is required to localizes methotrexate (MTX) in the synovial joint is needed to treat inﬂammation
in rheumatoid arthritis (RA). The present investigation aims at exploring the potential of fatty acid vesicles for the topical delivery
of methotrexate. Vesicles were prepared by ﬁlm hydration method using oleic acid as a fatty acid principal component. Developed
vesicles were characterized for size, size distribution, shape, in vitro release, pH dependent, and storage stability. Interaction
between MTX and oleic acid was investigated using diﬀerential scanning calorimetry. The MTX amount permeated through rat
skin was three- to fourfold higher using oleic acid compared to those from plain drug solution or carbopol gel. At the end of
the skin permeation assay using ufasomes, up to 50% of the administered dose was found in the skin. These results suggest that
methotrexateencapsulatedinoleicacidvesiclesmaybeofvalueforthetopicaladministrationofMTXinthetreatmentofpsoriasis.
1.Introduction
Rheumatoid arthritis (RA) is a chronic inﬂammatory disease
of unknown etiology and complex multifactorial pathogene-
sis. It is characterized by progressive and irreversible damage
ofthesynovial-linedjoints,resultinginthelossofjointspace,
bone, and a decrease in joint function and deformity [1]. RA
is usually treated ﬁrst with a nonsteroidal antiinﬂammatory
drug (NSAID). However, current RA treatment favors early
use of slow acting disease modifying anti-rheumatic drugs
(DMARDs) because DMARDs have the potential to prevent
or reduce joint damage. Therefore, they are used early in the
treatment of RA and usually no later than 3 months after the
commencement of NSAID treatment [2, 3]. Methotrexate
(MTX) is one of the most frequently used DMARDs in the
treatment of RA. Although the exact mechanism of action
is still unclear, the eﬃcacy of MTX is related to its cytotoxic
andanti-inﬂammatoryeﬀects[4].Whenadministeredinlow
weekly oral doses, MTX eﬀectively suppresses inﬂammation
in RA [5]. However, systemic toxicity eﬀects such as stom-
atitis, nausea, bone marrowdepression, and liver toxicity can
limit the oral use of this drug [6]. To reduce these eﬀects,
clinical studies have been done with topical methotrexate
[7, 8]. A major problem in topical administration of
methotrexate is that the drug is hydrosoluble and is mostly
in the dissociated form at physiological pH: its capacity for
passive diﬀusion is thus limited. One of the possibilities
for increasing the penetration of drugs through the skin
is the use of vesicular systems such as liposomes. Due to
their biocompatibility and capability of incorporating both
hydrophilic and lipophilic drugs, liposomes have recently
been investigated as transdermal drug delivery systems [9].
The strategy of using liposomes is of interest but remains
controversial owing to their large minimum size. To date,
no consensus exists on whether or not administration of
liposomescanleadtopenetrationintoorthroughintactskin,
but agreement is general that most liposomes do not reach
deep into intact skin.
In our previous study, we evaluated oleic acid vesicles as
a carrier for sustained delivery of o 5-FU and zidovudine,
Sharma et al., 2011 [10, 11], using topical/transdermal route.
Therefore, aim of present investigation was to explore the
potential of oleic acid vesicles as alternate for topical delivery
of MTX.2 ISRN Pharmaceutics
2. Experimental
2.1.PreparationofFattyAcidVesicles. Oleicacidvesicleswere
prepared by ﬁlm hydration method using Rota evaporator,
as reported earlier by [12] with minor modiﬁcation. Brieﬂy,
oleic acid of optimized molarity (80mM), span80, and MTX
was dissolved in methanol in a round bottom ﬂask followed
by evaporation of solvent under vacuum using a rotary
evaporator (Roteva Equitron, Mumbai, India) (600mmHg,
100rpm). For complete removal of any possible traces of
methanol and also to prevent the formation of emulsion
due to the residual organic solvent the completely dried
ﬁlm in rota evaporator was left overnight which was then
hydrated at ambient temperature for 1h with alkaline
borate buﬀer (pH 7.4). The prepared vesicles were then
sonicated to form the uniform size vesicular dispersion.
Optimization and selection of carrier for topical delivery
were performed by altering the ratios of oleic acid and
MTX (Table 1). Unentrapped drug was separated from the
vesicle dispersion by using gel chromatography on oleic
acid vesicle presaturated Sephadex G-50 minicolumn using
borate buﬀer as eluant. The encapsulation eﬃciency was
determined by disrupting the eluted vesicles using sodium
hydroxide solution (1M) and subsequence estimation of
released MTX, as entrapped drug.
2.2. Preparation of Plain MTX Gel. MTX containing car-
bopol gel was prepared by the method reported by Zao et
al. (2007). Brieﬂy, 1% w/v of carbopol 940 was dispersed
into puriﬁed water with the help of a vortex shaker (Tarsons,
Kolkata, India) and allowed to hydrate for 4-5h. The pH
value of the gel was adjusted to 7.4 using triethanolamine.
During preparation of the gel, to avoid any air entrapment,
the solution was agitated slowly. Under gentle mechanical
mixing for 5min, plain drug gel was prepared by using
an equivalent amount of MTX solution into the previously
made carbopol gel in a 2:1 ratio.
2.3. pH Dependent Stability. Prepared vesicles were then
incubated optimized with buﬀers of pH 8.5, 7.4, 6.5, and
5.5 to study the eﬀect of pH on the stability. Drug release
behavior was monitored by taking sample predetermined
time intervals, the samples were withdrawn and centrifuged
at 14,000rpm for 30min. The supernatant was analyzed for
released free drug. The amount of drug leached was then
calculated by the following formula:
%Drug diﬀused =
Amount of free drug
Total drug
×100. (1)
Simultaneously, the incubated vesicles were observed
for any change in morphology and size using an optical
microscope. The studies were performed in triplicate.
2.4. Ufasomes Size Determination. The average diameter and
size distribution of ufasomes suspensions were determined
by photocorrelation spectroscopy using a 90 Plus Particle
Size Analyzer (Brookhaven Instrument, NY, USA) at a
ﬁxed angle of 90◦ and at 25◦C. Ufasomes suspensions
were suitability diluted with phosphate buﬀer (pH 7.4) and
ﬁltered through a 1m polycarbonate membrane to minimize
interference particulate matter before sizing. Each measure-
ment was in triplicate.
2.5. Entrapment Eﬃciency. The entrapment eﬃciency, calcu-
lated as percentage of initial MTX incorporated into lipos-
omes, was determined after removing free MTX. Subse-
quently, ufasomes were redispersed in phosphate buﬀer (pH
7.4)containing2%TritonX-100.Theﬁnalclearsolutionwas
analyzed by HPLC for MTX content Determination of MTX
release.
2.6. Diﬀerential Scanning Calorimetry (DSC). DSC was per-
formed with a Perkin-Elmer diﬀerential calorimeter (DSC7,
Perkin-Elmer, Norwalk, CT, USA). Oleic acid (a), oleic
acid—MTX vesicles (b), oleic acid—MTX 8:2 vesicles (c),
and oleic acid—MTX 9:1 vesicles (d) were placed in con-
ventional aluminum pan, and a scan speed of 2◦C/min was
employed. The weight of each sample was 12–15mg.
2.7. The In Vitro Release of MTX Was Determined Using the
Nonequilibrium Dialysis Method. A locally fabricated cell
system consisting of a donor and a receptor compartment
of equal volume (1.5mL) separated by a dialysis membrane
(cutoﬀ 12,000Da) was used. Receiving medium was phos-
phate buﬀer (pH 7.4), and the cell was thermostated at 37◦C.
MTX aqueous solution and liposome suspensions were used
as donor formulations. At ﬁxed times, the receptor solution
was tipped out and used for HPLC analysis and the cell was
reﬁlled with fresh phosphate buﬀer. The drug concentration
was determined by HPLC.
The results were evaluated as apparent permeability con-
stant of MTX (Kdappcmmin−1) calculated from the slope
of the straight line obtained by plotting the amount of MTX
diﬀused from the donor formulation versus time, assuming
pseudo-zero-order kinetics.
2.8. Skin Irritation Studies. The oleic acid vesicle dispersions
were tested for skin irritation as they have been reported
to cause skin irritation owing to free acidic group present
in the structure. The skin irritation test revealed negligible
irritation scores in the case of oleic acid vesicle dispersion,
while when the free oleic acid was applied, it produced
erythematic events, as shown by the primary irritation scores
(data not shown). The eﬀect of formulations of the guinea
pig skin after 24, 48, and 72h of application was also
visualized. It was found that oleic acid vesicles demonstrated
skin tolerance of fatty acids may be because active groups
of acid engaged in self-assembly, forming a noninvasive
continuous membrane in the form of vesicles.
2.9.InVitroPermeationandSkinDepositionStudies. Ratskin
was used for permeation experiments using a vertical cell,
as proposed by [13]. The hair of the outer skin surface was
removed with dissecting scissors brought as close as possible
to the skin without damaging it. The skin was carefully
dissected with a scalpel and forceps. The skin was rinsedISRN Pharmaceutics 3
Table 1: Size and entrapment eﬃciency of the prepared oleic acid vesicles.
Formulation code Oleic acid: 5-MTX (molar ratio) Entrapment eﬃciency Particle size (nm) PDI
UF-1 9:1 (39.4 ±2.1) 505 ± 15 0.367 ±0.037
UF-2 8:2 (45.4 ±2.1) 523 ± 12 0.468 ±0.037
UF-3 7:3 (51.0 ±4.2%), 632 ± 17 0.262 ±0.037
UF-4 6:4 (49.4 ±2.7) 531 ± 16 0.489 ±0.037
UF-5 5:5 (48.4 ±2.4) 404 ± 13 0.581 ±0.037
UF-1,2,3-ufasomes with diﬀerent molar ratio of drug.
with normal saline and prehydrated by ﬂoating it with the
stratum corneum upward on 0.002% w/v aqueous sodium
a z i d et om a i n t a i na ni nv i v ot r a n s e p i d e r m a lh y d r a t i o n
gradient [14]. The skin was then sandwiched between donar
and receptor compartment with the stratum corneum side
upwards. The receptor chamber was ﬁlled with 6mL of
buﬀer solution pH (7.4). The test formulation (1mL) was
transferred to donar compartment, which had an available
diﬀusion area of 1.7cm2 and left to dry. MTX aqueous
solution was used a control formulation. The content of
the receptor cell, continuously stirred at 37◦C, was removed
at appropriate intervals for HPLC determination, and the
cell was immediately reﬁlled with fresh receptor solution.
At the end of the permeation experiments (24h), the skin
surface was washed ﬁve times with ethanol:buﬀer solution
pH 7.4 (1:1) then with water to remove excess drug from the
surface. The skin was then cut into small pieces. The tissue
was further homogenized with ethanol:buﬀer solution pH
7.4 (1:1) and left for 6h at room temperature. After shaking
for 5min and centrifuging for 5min at 5000rpm, the MTX
content was determined by HPLC. Each experiment was
repeated at least in triplicate from two diﬀerent batches of
the formulation.
2.10. HPLC Assay. The concentration of MTX was deter-
mined by HPLC. The HPLC system consisted of a pump
(LC 20-AD), an UV detector (RF-551, λ = 302nm), a
data station (Shimadzu, Kyoto, Japan), and a 5cm C18
column (LiChrospher, Merck, Darmstadt, Germany). The
mobilephasecomprisedmethanol/acetonitrile/pH5.4buﬀer
solution (8.5/6.5/85v/v) and was delivered at a ﬂow rate
of 0.6mLmin−1. The injection volume was 20L, and the
relative retention time was found to be 9.8min.
3. StabilityStudies
Stability of the product may be deﬁned as the capability of a
particularformulationtoremainwiththephysical,chemical,
therapeutic, and toxicological speciﬁcations. The optimized
formulation (FAV-3) was selected for stability study on
the basis of its in vitro performance and stored in tightly
closed glass vials at room temperature and in refrigerator
(4 ± 2◦C). Following parameters were evaluated at diﬀerent
time intervals (20, 40, and 60 days). The formulations were
stored in 10mL glass vials at refrigeration temperature (4 ±
2◦C) and room temperature for a period of 2 months.
The samples were analyzed at predetermined time intervals
visually and under optical microscope for the change in
consistency and appearance of drug crystals. Vesicle size and
size distribution were determined at deﬁnitive time intervals
foraperiodof2monthsusingstageeyepiecemicrometerand
haemocytometer, respectively, as described earlier.
4. Results
4.1. Fatty Acid Vesicle Characterization. Multilamellar oleic
acid vesicles were prepared by ﬁlm hydration method by
varying oleic acid-to-MTX molar ratios. Hydration was
aﬀe c t e da tr o o mt e m p e r a t u r ef o r1 ht oe n a b l ec o m p l e t e
hydration. The speed of rotation and concentration of oleic
acid inﬂuence the thickness, uniformity, and duration of
time interval of the ﬁlm. The rotation speed of 100rpm
was observed to yield a uniform thin lipid ﬁlm, while lower
and higher rate, of rotation resulted in perceptible non-
vesicular aggregated artifacts. The developed formulations
were further characterized for size, PDI, and entrapment
eﬃciency (Table 1) .Th es t u d i e sc a rri edo u td e m o n s tra t edn o
signiﬁcant diﬀerence in the entrapment eﬃciency; however,
the mean entrapment eﬃciency of the vesicles increased with
anincreaseinthemolarquantityofMTXupto7:3oleicacid
to MTX ratio (51.0 ± 4.2%). Beyond this ratio, no further
increase in drug entrapment was recorded. The vesicular
sizes were obtained in the range of 500nm to 1μm. The oleic
acid vesicles dispersions obtained were mostly polydisperse;
however, at 7:3 oleic acid-to-MTX ratio the dispersity was
recorded to be 0.262 ± 0.037. The photomicrographs depict
the spherical nature of the oleic acid vesicles (Figure 1(a)).
Further, in addition, the TEM study conducted conﬁrmed
the ultrastructure of oleic acid vesicles which revealed
multilamellarity of vesicles (Figure 1(b)).
4.2. Diﬀerential Scanning Calorimetry. Diﬀerential scanning
calorimetry was carried out to evaluate the interactions
between MTX and oleic acid with diﬀerent molar ratio;
Figure 2 reports the thermograms. HPC was used for DSC
measurements because its transition temperature (Tm) can
easily be measured. The DSC trace of oleic acid vesicle
showed a an enthalpy of 37.8 ± 0.4Jg −1 and peak transition
at 48.9 ± 0.2◦C. Incorporation of diﬀerent molar ratio into
oleic reduced the Tm value to 48.6 ± 0.2◦C and the enthalpy
to 35.7±0.5Jg −1.ThedecreaseinTmvaluemayindicatethat
the diﬀerent molar perturbs the packing characteristics and,
thus, ﬂuidizes the lipid bilayer. The presence of MTX did not4 ISRN Pharmaceutics
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Figure 2: Diﬀerential scanning calorimetry traces of oleic acid (a),
oleicacid—MTXvesicles(b),oleicacid—MTX8:2vesicles(c),and
oleic acid—MTX 9:1 vesicles (d).
change either Tm or the enthalpy values, indicating that this
molecule is entrapped in the hydrophilic core of oleic acid.
4.3. Drug Release Studies
4.3.1. MTX Release. T h er a t eo fr e l e a s eo fM T Xf r o m
ufasomal gel formulation was signiﬁcantly lower (P<0.05)
than that from UF-3 gel formulation and drug solution
(Figure 3). Maximum amount of MTX was released (97.2 ±
4.5%) within 4hr from drug solution, while only 18.43 ±
1.5% and 16.38 ± 1.4% were released from UF-3 suspension
and gel formulations, respectively. These results clearly
indicatedthatthereleaseofMTXgelwaseﬀectively retarded.
For the characterization of the release kinetics, the in
vitro drug release data was ﬁtted to zero-order, ﬁrst-order,
and Higuchi equations [15]. Kinetic release parameters
of diﬀerent formulations are summarized in Table 3.T h e
permeation studies revealed a zero-order release of MTX
from ufasomal gel formulation (r2 = 0.9961). Since the
concentration of drug is in equilibrium with the inner
surface of the ufasomal vesicle membrane and diﬀusion path






























Figure 3: % drug release form diﬀerent formulation across cello-
phane membrane.
is generally expected with vesicular systems [16]. The release
rate constant (logK) for UF-3 gel, UF-3 gel suspension, and
carbopol gel was found to be 0.7327, 0.8143, and 0.9923,
respectively. The signiﬁcantly (P<0.05) lower log K value
for MTX release from UF-3 gel as compared to UF-3
suspension and carbopol gel indicated that incorporation
of oleic acid vesicles into carbopol gel further sustained its
release.
4.3.2. In Vitro Permeation and Skin Deposition. The skin
permeation study was conducted on optimized formulation
prepared at a 7:3 fatty acid:drug ratio (pH 7.4) (highest
entrapment eﬃciency and more uniform sized vesicles). To
normalize the eﬀect of pH on skin permeation, the plain
pH of drug gel was also adjusted to pH 7.4. A signiﬁcant
increase in the skin permeation of MTX was recorded from
oleic acid vesicle dispersion in comparison to plain gel
(Figure 4). The amount of MTX permeated from the plain









































Figure 4: Amount of drug permeated from diﬀerent formulation
across rat skin for 24hr.
Table 2: % Cumulative amount of methotrexate permeated after
24h (microgram MTX) and skin deposition (percentage MTX)
from diﬀerent vesicular formulations and from aqueous control
solution.
MTX (μg) MTX (% age)
Aqueous control solution 5.06 ±0.84% 13 ± 3
carbopol gel 12.5 ±2.83 0 ± 5
UF-3 21.5 ±4.54 3 ± 4
UF gel 29.55 ±4.35 2 ± 6
UF suspension 19.55 ±4.64 5 ± 5
application of an equivalent amount of drug in vesicular
dispersion was signiﬁcantly high, that is, 52 ± 6%. The
permeation parameters were calculated by plotting a curve
between cumulative amounts of drug permeated per unit
area (μg/cm2) versus time. The ﬂux was obtained from the
slope of the linear portion of the graph. The transdermal
permeation rate constants obtained were higher for oleic
acid vesicle dispersions (17 ± 1.4μg/h/cm2) than the plain
drug gel (3.5 ± 0.7μg/h/cm2). It has also been observed that
drug retained in the skin was more in the case of vesicular
dispersion(29.55±4.3)ascomparedtoplaindruggel(5.06±
0.84%) (Table 2).
During last decade, several studies have compared trans-
dermal MTX transport from diﬀerent vehicles, but the data
are quite controversial; this may be due to several factors
such as inﬂuence of the components on the skin barrier
properties, on the diﬀerent species and types of skin and on
diﬀerent experimental procedures used for study. In partic-
ular, [17] used 50% propylene glycol in aqueous medium
at diﬀerent pH and found a drug permeation parameters
through human skin similar to that obtained from oleic acid
vesicles, while [17, 18] reported very low MTX permeation
from aqueous solutions. Other studies report MTX ﬂuxes
from vesicles [19]; the amount permeated through rat skin,


































Figure 5: pH-dependent release behavior of drug from oleic acid
vesicles dispersion.
is similar to that now obtained from KG liposomes, while
very low permeation 0 values were reported from other
vesicular formulations [20]. However, to compare these last
data, the possible enhancing eﬀect of oleic acid must be
considered. Table 3 also shows the residual amount of MTX
in the skin after 24h administration of diﬀerent prepara-
tions. Surfactant with oleic acid incorporated promoted the
transfer of MTX into rat skin. Skin deposition increased
by a factor of 3 compared with either aqueous solution or
carbopol gel.
In accordance with the results of our previous study
Sharma et al. 2011 [21], where oleic acid vesicles applied
nonocclusively, signiﬁcantly improved in vitro skin delivery
of 5-FU compared with aqueous solution. It is supposed that
oleic acid can penetrate the skin whole, carrying the MTX
entrapped in the hydrophilic core. Subsequently, a partition
of intact vesicles into the deeper layers of the stratum
corneum [22, 23] leads to high drug accumulation and only
little vesicle materials probably reaches the deepest layers
of the corneum and then the viable epidermis. However,
other determinations, such as composition and vesicle size
in donor and receiving medium, freeze-fracture electron
microscopyorconfocallaserscanningmicroscopyoftheskin
will be necessary to conﬁrm this hypothesis. In conclusion,
ufasomes obtained using oleic acid, a safe surfactant widely
used in cosmetics, applied nonocclusively, improve in vitro
skin delivery of MTX compared to either aqueous solution
or normal liposomes. The enhanced accumulation of MTX
within the skin might help to optimize targeting of this drug,
creating new opportunities for well-controlled and modern
topical application of MTX in the treatment of RA.
4.3.3. pH-Dependent Stability. In order to understand, study
to see the inﬂuence of pH dependent nature of the oleic acid
vesicles was carried out as it provided useful information on
topical drug delivery potential and characteristics of oleic
acid vesicles since the pH of skin is 5.5. It was observed
that the release from vesicles is highly pH-dependent and
on lowering the pH from 8.5 to 5.5, only 20% of the drug
remained in vesicles to be released after 8h of incubation in
buﬀer of pH 5.5 as compared to residual drug estimated, that
is,71%atpH8.5(Figure 5).Thediﬀerencesindrugdiﬀusion6 ISRN Pharmaceutics
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(c)
Figure 6: Photomicrograph of UF-3 formulation (a) pH (7.4), (b) pH (5.5), (c) pH (8.5).




Zero order First order Higuchi 3∗Logk
UF-3 gel 0.9961 0.8843 0.9792 0.7327 0.7574
UF-3 0.9742 0.7931 0.9534 0.8143 0.8304
Carbopol gel 0.8227 0.9964 0.9346 0.9923 0.9953
Plain drug 0.6081 0.9582 0.8687 1.2465 1.2314
∗∗Coeﬃcient of correlation, 3∗kinetic constant, and 4∗diﬀusional exponent indicative of the mechanism of drug release.
recorded at pH 8.5 and 7.4 were not signiﬁcant (P>0.01).
Therefore, further studies were continued by adjusting the
pH of vesicles suspension to 7.4, since higher pH values
may cause skin irritation and may not be acceptable for
topical application. Simultaneously, morphological changes
in vesicles size and shape were also observed with changing
pH.Theresultsdisplayedanincreaseinthesizeofthevesicles
at low pH values (Figure 6).
5. Discussion
Critical factor for formation fatty acid vesicles that is,
ufasomal formulation, is pH which controls the degree of
ionization of fatty acid [24, 25]. Fatty acid (oleic acid)
assembled into vesicles if pH equals the pKa of the acid
(8.5), because, at this pH, ∼50% of the carboxylic acid is
ionized and transforms into ionized amphiphile(s) with a
tendency to form vesicles aggregates. The acid is present as
ionic RCOO− as well as neutral RCOOH species. In such
conditions, each ionized group is stabilized through a strong
hydrogen bond formed with the neutral molecules. The
negative charge present on the ionized carboxylic group is
shared between two adjacent fatty acid molecules, that is,
ionized and unionized and, thus, results in the formation
of typical dimers. The hydrophobic hydrocarbon chain of so
formeddimersprotectsitselffromtheaqueouscompartment
and thus orients to form an enclosed bilayer structure that
minimizes the interaction between the hydrocarbon chain
and water. The ratio of protonated and deprotonated group
seems also critical in the process of vesiculation. This is
possible only if the concentration of the fatty acid in aqueous
dispersion exceeds the critical vesicle concentration (cvc),
which is reportedly 80mM for oleic acid [26]. The stability
of the vesicles is attributed to the strong hydrogen bond-
basedinteractions betweentheprotonated anddeprotonatedISRN Pharmaceutics 7
groups, namely, RCOO− ··· HOOCR as suggested and
reported by [27–30]. Therefore, fatty acid vesicles were
evaluated to assess their eﬃcacy in delivering the bioactives
to and through stratum corneum of the skin. The drug
methotrexate (MTX) was used as a model drug.
In bid to understand the eﬀect of drug:oleic acid ratio
on the encapsulation study for MTX was carried out. It
was observed that the drug bearing capacity of the oleic
acid vesicles primarily depends upon the molar ratio of
oleic acid and MTX. The entrapment eﬃciency increased
up to oleic acid:drug molar ratio 7:3, beyond this ratio
further increase in the amount of drug reduced the degree of
drug encapsulation. As further addition of drug could have
destabilized the vesicle membrane which in turn lead to the
leakage of content due to the saturation of drug in the bilayer
domain. Based on physicochemical characterization studied,
UF-3 was selected for further studies. Further, by comparing
the drug release data of oleic acid vesicles with that of MTX
solution, it was concluded that the release of MTX from
the vesicle was slow, controlled, and uniform as compared
to plain drug solution. The pH-dependent stability behavior
substantiates that drug diﬀusion across the skin may increase
with a decrease in the pH of the vesicles dispersion. Thus, the
increased diﬀusion of drug from the vesicles at low pH may
haveresultedduetodecreasedstabilityofthevesiclesatlower
pH. This further suggests that vesicles tend to fuse when they
are exposed to low pH. This particularly holds for the pH
that is lower than physiological pH. Moreover, the vesicles
incubated in buﬀers of diﬀerent pH were analyzed under an
optical microscope. The optical images clearly revealed that
the size of the vesicles slumped with the drop in the pH,
proving the pH-dependent fusogenic tendency of vesicles.
6. Conclusion
In conclusion, ufasomes obtained using oleic acid, a safe
surfactant widely, applied nonocclusively, improve in vitro
skin delivery of MTX compared to either aqueous solution
or normal liposomes. The enhanced accumulation of MTX
within the skin might help to optimize targeting of this drug,
creating new opportunities for well-controlled and modern
topical application of MTX in the treatment of RA.
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